Macomics Ltd. announced that it has entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical Co. Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest using its ENIGMACTM macrophage drug discovery platform.

Ono will have an exclusive option to license global rights to the candidates for further development and commercialization. Macomics will receive an up-front payment, R&D funding, and success-based milestone payments, as well as tiered royalties based on global net sales. Macomics is exploiting the potential of macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology.

Macomics' ENIGMAC macrophage drug discovery platform integrates large volume human data sets, custom cell models, and proprietary human macrophage genome editing capability to discover novel targets and unlock disease specific target biology. Macomics' ENigMAC macrophage drug discovery platforms integrates large volume human data sets., custom cell models, and proprietary Human macrophage genome editing capability To discover novel targets and unlock diseasespecific target biology. Macomics'ENIGMAC macrophage drug Discovery platform integrates large volume human data set, custom cell models, and exclusive human macrophage genome editing capabilities to discover novel targets and unlock Disease specific target biology.

Macomics' ENIGMAC macrophage drug discovery platform integrates large volume human data sets, custom cell models, and proprietary human macrophage genome editing capability to discover novel targets and unlock disease specific target biology. Macrophages (TAMs) are often the most abundant immune cell many types of cancer and modulating TAMs can enhance the body's ability to fight cancer.